Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Recruiting · NCT04322890 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
- Age ≥ 18 years.
- Histologically or cytologically confirmed, Stage IV NSCLC.
- Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.
- ECOG 0-1.
- Predicted survival ≥ 12 weeks.
- Adequate bone marrow hematopoiesis and organ function
- Presence of measurable lesions according to RECIST 1.1.
Exclusion criteria
- The patient did not match from the Inclusion Criteria.
Where it is running
1 location listed.
- Yongchang Zhang - Changsha, Hunan, China